Post-transplant lymphoproliferative disorders
Top Cited Papers
- 28 January 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Disease Primers
- Vol. 2 (1), 15088
- https://doi.org/10.1038/nrdp.2015.88
Abstract
Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve uncontrolled proliferation of lymphoid cells as a consequence of extrinsic immunosuppression after organ or haematopoietic stem cell transplant. PTLDs show some similarities to classic lymphomas in the non-immunosuppressed general population. The oncogenic Epstein–Barr virus (EBV) is a key pathogenic driver in many early-onset cases, through multiple mechanisms. The incidence of PTLD varies with the type of transplant; a clear distinction should therefore be made between the conditions after solid organ transplant and after haematopoietic stem cell transplant. Recipient EBV seronegativity and the intensity of immunosuppression are among key risk factors. Symptoms and signs depend on the localization of the lymphoid masses. Diagnosis requires histopathology, although imaging techniques can provide additional supportive evidence. Pre-emptive intervention based on monitoring EBV levels in blood has emerged as the preferred strategy for PTLD prevention. Treatment of established disease includes reduction of immunosuppression and/or administration of rituximab (a B cell-specific antibody against CD20), chemotherapy and EBV-specific cytotoxic T cells. Despite these strategies, the mortality and morbidity remains considerable. Patient outcome is influenced by the severity of presentation, treatment-related complications and risk of allograft loss. New innovative treatment options hold promise for changing the outlook in the future.This publication has 181 references indexed in Scilit:
- Molecular Pathogenesis of B-Cell Posttransplant Lymphoproliferative Disorder: What Do We Know So Far?Journal of Immunology Research, 2013
- Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse ModelCell, 2012
- Decreased NKp46 and NKG2D and elevated PD‐1 are associated with altered NK‐cell function in pediatric transplant patients with PTLDEuropean Journal of Immunology, 2011
- Syk Activation of Phosphatidylinositol 3-Kinase/Akt Prevents HtrA2-dependent Loss of X-linked Inhibitor of Apoptosis Protein (XIAP) to Promote Survival of Epstein-Barr Virus+ (EBV+) B Cell LymphomasPublished by Elsevier BV ,2011
- Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant RecipientsAmerican Journal of Transplantation, 2011
- Risk factors for early‐onset and late‐onset post‐transplant lymphoproliferative disorder in kidney recipients in the United StatesAmerican Journal of Hematology, 2010
- The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisalVirus Research, 2009
- Tumor-derived Variants of Epstein-Barr Virus Latent Membrane Protein 1 Induce Sustained Erk Activation and c-FosPublished by Elsevier BV ,2008
- Epstein–Barr virus, rapamycin, and host immune responsesCurrent Opinion in Organ Transplantation, 2008
- Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With AlemtuzumabAmerican Journal of Transplantation, 2007